Leap Therapeutics, Inc. (LPTX)
NASDAQ: LPTX · Real-Time Price · USD
0.4785
+0.0109 (2.33%)
At close: Oct 24, 2025, 4:00 PM EDT
0.4825
+0.0040 (0.84%)
After-hours: Oct 24, 2025, 7:35 PM EDT
Leap Therapeutics Employees
Leap Therapeutics had 52 employees as of December 31, 2024. The number of employees decreased by 2 or -3.70% compared to the previous year.
Employees
52
Change (1Y)
-2
Growth (1Y)
-3.70%
Revenue / Employee
n/a
Profits / Employee
-$1,267,673
Market Cap
27.11M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52 | -2 | -3.70% |
| Dec 31, 2023 | 54 | 10 | 22.73% |
| Dec 31, 2022 | 44 | 8 | 22.22% |
| Dec 31, 2021 | 36 | 6 | 20.00% |
| Dec 31, 2020 | 30 | 4 | 15.38% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LPTX News
- 4 days ago - Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 - PRNewsWire
- 15 days ago - Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy - PRNewsWire
- 18 days ago - Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy - PRNewsWire
- 4 weeks ago - Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 - PRNewsWire
- 2 months ago - Leap Therapeutics Reports Second Quarter 2025 Financial Results - PRNewsWire
- 4 months ago - Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives - PRNewsWire
- 5 months ago - Leap Therapeutics Reports First Quarter 2025 Financial Results - PRNewsWire
- 6 months ago - Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting - PRNewsWire